Validation of a Transcriptome-Based Assay for Classifying Cancers of Unknown Primary Origin

Combining diagnostic prediction tests (e.g., Tempus TO) with sequencing-based variant reporting (e.g., Tempus xT) may expand therapeutic options for patients with cancers of unknown primary or uncertain histology.